Wilmington Savings Fund Society FSB Buys Shares of 2,515 Cencora, Inc. (NYSE:COR)

Wilmington Savings Fund Society FSB acquired a new stake in Cencora, Inc. (NYSE:COR - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 2,515 shares of the company's stock, valued at approximately $566,000.

Other institutional investors have also recently made changes to their positions in the company. Pacer Advisors Inc. boosted its position in Cencora by 6,855.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company's stock valued at $464,874,000 after buying an additional 2,035,679 shares during the period. Bank of Montreal Can boosted its holdings in shares of Cencora by 136.8% during the second quarter. Bank of Montreal Can now owns 641,887 shares of the company's stock worth $153,623,000 after purchasing an additional 370,841 shares during the period. American Century Companies Inc. grew its stake in shares of Cencora by 155.0% in the second quarter. American Century Companies Inc. now owns 598,438 shares of the company's stock worth $134,828,000 after purchasing an additional 363,796 shares during the last quarter. Wellington Management Group LLP increased its holdings in Cencora by 7.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock valued at $1,168,927,000 after purchasing an additional 338,452 shares during the period. Finally, Two Sigma Advisers LP raised its position in Cencora by 21.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company's stock valued at $368,771,000 after purchasing an additional 292,600 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Cencora Stock Down 1.0 %

COR stock traded down $2.36 on Monday, reaching $229.88. 1,630,523 shares of the company traded hands, compared to its average volume of 1,387,907. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The firm has a fifty day simple moving average of $238.36 and a 200-day simple moving average of $234.14. Cencora, Inc. has a one year low of $199.37 and a one year high of $253.27. The company has a market cap of $44.43 billion, a P/E ratio of 30.60, a price-to-earnings-growth ratio of 1.54 and a beta of 0.45.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.96%. This is an increase from Cencora's previous quarterly dividend of $0.51. The ex-dividend date of this dividend was Friday, November 15th. Cencora's dividend payout ratio is 29.29%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Barclays boosted their target price on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research note on Thursday, November 7th. Leerink Partners dropped their target price on shares of Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a research report on Monday, October 7th. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $280.00 to $287.00 and gave the company an "overweight" rating in a research report on Wednesday, August 21st. Evercore ISI increased their price target on shares of Cencora from $250.00 to $285.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. Finally, StockNews.com downgraded Cencora from a "strong-buy" rating to a "buy" rating in a report on Friday, September 20th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $275.60.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 50,000 shares of the company's stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the transaction, the chairman now directly owns 326,557 shares of the company's stock, valued at $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 93,018 shares of company stock worth $22,478,942. 15.80% of the stock is owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.